linked immunosorbent assay (ELISA) and westernblot. The difference expression of QSOX1/2 between tumor and para-cancerous tissues in TCGA-Pancancer database was analyzed by bioinformatics method. The difference gene analysis and pathway analysis of QSOX1/2 high and low expression groups were performed by Bayesian method, and the correlation between QSOX1/2 expression level and survival and clinical stage was further analyzed. In vitro, the ability to synthesize Lp(a) of HepG2 cells after QSOX1/2 deletion was verified by Immunoturbidimetric assay (ITA), and cell proliferation was analyzed by EdU and flow cytometry. Results: We found that serum Lp(a) concentrations in 27.5% of patients in the study cohort were higher than the mean value in the normal medical cohort. Serum Lp(a) concentrations in cancer patients were positively correlated with QSOX1/2 serum concentrations (R¼0.34，P<0.005). In the TCGA-Pancancer database, the expression level of QSOX1/2 in tumor tissues were higher than that in para-cancerous tissues, and the over expression of QSOX1/2 may be related to abnormal regulation of tumor cell cycle. In vitro, experiments showed that the expression of QSOX1/2 regulated the extracellular synthesis ability of Lp(a). Silencing QSOX1/2 genes significantly inhibited the proliferation of tumor cells. Conclusion: The abnormal expression of QSOX1/2-Lp(a) can be used as a potential bio-marker for the poor prognosis of cancers. And targeted QSOX1/2 treatment may inhibit tumor growth with this molecular subtype. Zhongshan School Of Medicine, Sun Yat-sen University, Guangzhou/CN Background: Docosahexaenoic acid and eicosapentaenoic acid have been reported to be associated with lung cancer risk; however, it remains unknown whether docosapentaenoic acid (DPA), another kind of n-3 PUFA, is related to lung cancer risk. The aim of this study is to investigate the causal effect of DPA on lung cancer with Mendelian randomization (MR) method. Method: With a two-sample MR approach, we analyzed the summary data from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE, 8,866 individuals of European ancestry) Consortium and International Lung Cancer Consortium (ILCCO, 11348 lung cancer cases and 15861 controls; European ancestry). Three single nucleotide polymorphisms (SNPs) that were genome-wide significant (p<5*10-8; linkage disequilibrium r2 < 0.1) for plasma DPA levels in CHARGE were explored for their associations with lung cancer risk in the ILCCO. Analysis for two different histologic subtypes of lung cancer (adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC)) was performed to investigate whether the effect of DPA is associated with the histology of lung cancer. To investigate whether lung cancer might be a causal factor for DPA, we performed an MR analysis in the opposite direction using 3 SNPs linked to lung cancer. Evidence of directional pleiotropy averaged across all variants was sought using MReEgger regression. Results: Our results indicated that genetically predicted higher DPA level has a positive association with lung cancer, where one percent higher DPA was associated with a 2.01 folds risk of lung cancer (odds ratio [OR]: 2.01, 95%
Background: Docosahexaenoic acid and eicosapentaenoic acid have been reported to be associated with lung cancer risk; however, it remains unknown whether docosapentaenoic acid (DPA), another kind of n-3 PUFA, is related to lung cancer risk. The aim of this study is to investigate the causal effect of DPA on lung cancer with Mendelian randomization (MR) method. Method: With a two-sample MR approach, we analyzed the summary data from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE, 8, 866 individuals of European ancestry) Consortium and International Lung Cancer Consortium (ILCCO, 11348 lung cancer cases and 15861 controls; European ancestry). Three single nucleotide polymorphisms (SNPs) that were genome-wide significant (p<5*10-8; linkage disequilibrium r2 < 0.1) for plasma DPA levels in CHARGE were explored for their associations with lung cancer risk in the ILCCO. Analysis for two different histologic subtypes of lung cancer (adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC)) was performed to investigate whether the effect of DPA is associated with the histology of lung cancer. To investigate whether lung cancer might be a causal factor for DPA, we performed an MR analysis in the opposite direction using 3 SNPs linked to lung cancer. Evidence of directional pleiotropy averaged across all variants was sought using MReEgger regression. Results: Our results indicated that genetically predicted higher DPA level has a positive association with lung cancer, where one percent higher DPA was associated with a 2.01 folds risk of lung cancer (odds ratio [OR]: 2.01, 95% CI 1.34-3.01; p¼7.40Â10À4). Besides, the similar causal trend was observed in both LUAD and LUSC (LUAD, OR 2.54, 95% CI 1.38-4.68, p¼2.84Â10À3; LUSC, OR 2.20, 95% CI 1.18-4.10, p¼1.29Â10À2). Additionally, lung cancer was not a causal factor for DPA. The results of MR-Egger regression analysis showed that there was no evidence for the presence of directional horizontal pleiotropy. Limitations of our study included that the underlying mechanisms of the causality between DPA and lung cancer were unknown and that the generality of our study needed to be confirmed. Conclusion: Genetically elevated DPA is positively associated with risk of lung cancer, which indicates that DPA plays an important role in lung cancer etiology. More work is needed to investigate the potential mechanisms and elucidate the roles of DPA in the etiology of lung cancer clearly. Keywords: Docosapentaenoic Acid, lung cancer, Mendelian Randomisation, Causality
Background: Lymphoepithelioma-like carcinoma (LELC), an unusual histological type of malignancy, occurs in almost all anatomic sites of body including lung and bronchus. Although with strong ties to Epstein-Barr virus infection, LELC at different sites has distinct clinical characteristics. Because of the rarity, it is however largely unclear whether LELC at different sites would lead to different prognosis, independent of clinical characteristics. Method: Based on the populationbased cancer cohort from the Surveillance, Epidemiology, and End Results database (SEER), we identified all LELC patients from year 1973 to 2015. According to tumor sites, we classified LELC patients into lung and bronchus, nasopharynx, and another eight most common sites. We studied overall survival as the primary outcome, while tumor characteristics as the secondary outcome. Results: In total, we identified 2079 LELC patients, of which 86 (4%) were positioned at lung and bronchus and 1208 (58%) at nasopharynx ( Figure 1A ). Patients with lung and bronchus LELC were older at diagnosis and with more advanced stage, as compared to nasopharyngeal LELC. The 5-year overall survival rates of LELC of lung and bronchus as well as nasopharynx were 35.8% and 59.5% in patients with localized stage ( Figure  1B) , while 35.1% and 55.5% in patients with regional stage (Figure 1C ), respectively. After controlling for tumor characteristics and treatment modes, patients with lung and bronchus LELC were associated with increased risk of overall mortality as compared with LELC of nasopharynx (HR 1.72, 95% CI 1.03 to 2.88). Conclusion: The demographics and clinical features of LELC greatly differ by organ of origin. Site may be an important predictor for survival in patients of LELC. Compared with LELC of nasopharynx, pulmonary LELC is associated with worse prognosis, independent of common prognostic factors. Keywords: SEER, Epidemiology, lung and bronchus, lymphoepithelioma-like carcinoma
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